Skip to main content
EYPT
NASDAQ Industrial Applications And Services

EyePoint's DURAVYU Phase 3 Wet AMD Trials Receive Third Positive DSMC Recommendation

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$13.3
Mkt Cap
$1.126B
52W Low
$5.3
52W High
$19.11
52W Position info
151% above low
Off High info
30% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

EYPT has more than doubled off its 52-week low of $5.3.

Summary

EyePoint, Inc. announced its third consecutive positive recommendation from the Data Safety Monitoring Committee for its pivotal Phase 3 DURAVYU program for wet AMD, reinforcing confidence ahead of mid-2026 topline data.


Key Events · Product Development and Regulatory · EYPT

  • Third Positive DSMC Recommendation

    The independent Data Safety Monitoring Committee (DSMC) issued its third consecutive positive recommendation for EyePoint's pivotal Phase 3 program evaluating DURAVYU for wet age-related macular degeneration (wet AMD).

  • Trials to Continue as Planned

    The DSMC recommended that both the LUGANO and LUCIA trials continue as planned with no protocol modifications, indicating no significant safety concerns.

  • Favorable Safety Profile Confirmed

    Interim masked safety data from the Phase 3 trials show a continued favorable safety profile for DURAVYU, consistent with safety observed in four previously completed clinical trials.

  • Progress Towards Topline Data

    All active patients in the treatment arm have reached their second DURAVYU dose, with over 35% receiving a third dose. Topline data for the LUGANO trial is on track for mid-2026, with LUCIA to follow shortly after.


Analysis · EYPT · Industrial Applications And Services

This 8-K reports a critical de-risking event for EyePoint's lead product candidate, DURAVYU, which is in pivotal Phase 3 trials for wet AMD. The third consecutive positive recommendation from the independent Data Safety Monitoring Committee (DSMC) confirms the safety profile and integrity of the trials, reducing the risk of unexpected setbacks. For a clinical-stage biopharmaceutical company, successful progression of late-stage clinical trials is paramount, especially given recent financial losses. This news builds significant confidence as the company approaches the crucial mid-2026 topline data readout, which will determine the drug's potential for market approval.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EYPT was trading at $13.30 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $5.30 to $19.11. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EYPT - Latest Insights

EYPT
Nov 19, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.281969
Real-time Price: $0.238543 info
Change: -$0.043426 (-15%) info
Market Cap: $26.648M info
EYPT
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.350
Real-time Price: $0.238543 info
Change: -$0.111457 (-32%) info
Market Cap: $26.648M info
EYPT
Nov 12, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.360
Real-time Price: $0.238543 info
Change: -$0.121457 (-34%) info
Market Cap: $26.648M info
EYPT
Nov 12, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.360
Real-time Price: $0.238543 info
Change: -$0.121457 (-34%) info
Market Cap: $26.648M info
EYPT
Oct 19, 2026, 9:22 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5443
Real-time Price: $0.238543 info
Change: -$0.305757 (-56%) info
Market Cap: $26.648M info